Rx&D

Rx&D

November 19, 2014 10:20 ET

Rx&D Announces Creation of the J. Mark Lievonen Scholarship at the Schulich School of Business

TORONTO, ONTARIO--(Marketwired - Nov. 19, 2014) -

Editor's Note: There is a photo associated with this Press Release.

Today Russell Williams, President of Canada's Research-Based Pharmaceutical Companies (Rx&D), is pleased to announce the creation of the J. Mark Lievonen Scholarship in Health Industry Management at the Schulich School of Business (Schulich) at York University, during the association's first-ever stakeholder conference celebrating its 100th-year anniversary.

"As the demand grows for strong and skilled healthcare management professionals, Rx&D is proud to further strengthen the link between industry and Canada's top academic centres," said Russell Williams.

The scholarship has been established in recognition of Mark Lievonen, President of Sanofi Pasteur Limited and outgoing Chair of the Rx&D Board.

"The J. Mark Lievonen scholarship is a tremendous vote of confidence by industry leaders in Schulich's MBA students, who are preparing to become Canada's next generation of leaders within this country's vitally important health industry," said Brenda Zimmerman, Director of Schulich's Health Industry Management Program.

The J. Mark Lievonen Scholarship will provide a second-year Master of Business Administration or International Master of Business Administration student in the Schulich Health Industry Management Program with a scholarship of approximately $7,000 to further their studies in the program. Rx&D and Sanofi Pasteur Limited have each contributed $25,000, and Mark Lievonen has contributed an additional $25,000. Schulich will match the annual income generated by their contributions, effectively creating an endowment valued at $150,000.

"As an alumnus of York, I am proud to be able to further the success of Schulich's Health Industry Management Program," said Mark Lievonen. "We recognize the need to prepare the best and brightest minds to take leadership roles in Canada's healthcare sector."

About Rx&D

Canada's Research-Based Pharmaceutical Companies is the national association representing the voice of Canada's innovative pharmaceutical industry. We serve our membership by advocating for policies that enable the discovery, development and delivery of innovative medicines and vaccines to improve the lives of all Canadians. We support our memberships' commitment to being a valued partner in the Canadian healthcare system. We represent more than 50 companies investing over $1-billion in R&D annually, fuelling Canada's knowledge-based economy, while contributing over $3-billion overall to Canada's economy. Guided by our Code of Ethical Practices, we work with governments, private payers, healthcare professionals and stakeholders in a highly ethical manner.

To view the photo associated with this press release, please visit the following link: http://www.marketwire.com/library/20141119-DPD_0142a.jpg

Contact Information